Evidence map›Paper›PMID 40434540›Full record

Trial reportJournal of neuro-oncology2025

Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.

Vihang Nakhate, Ina Ly, Alona Muzikansky, Otto Rapalino, Jeffrey C Allen, Jaishri O Blakeley, Jian L Campian, D Wade Clapp, Girish Dhall, Rakesh K Jain and 8 more

Registry-linked trialAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01767792 (Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01767792 phase2completednot on this map

Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation

TypeinterventionalSponsorUniversity of Alabama at BirminghamRan2013 to 2020Enrolled22ConditionsNeurofibromatosis Type 2, Progressive Vestibular SchwannomasArmsBevacizumab
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. A 3DNeuro-oncology advances
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Vihang NakhateCancer Center and Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Ina LyCancer Center and Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Alona MuzikanskyCancer Center and Department of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Otto RapalinoDepartment of Radiology, Massachusetts General Hospital, Boston, MA, USA.
Jeffrey C AllenDepartment of Pediatrics, New York University, New York, NY, USA.
Jaishri O BlakeleyDepartment of Neurology, Johns Hopkins University, Baltimore, MD, USA.
Jian L CampianDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
D Wade ClappDepartment of Pediatrics, Indiana University, Indianapolis, IN, USA.
Girish DhallDepartment of Genetics, University of Alabama, Birmingham, AL, USA.
Rakesh K JainDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.
Matthias A KarajannisDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Roger J PackerDepartment of Neurology and Pediatrics, Children's National Medical Center, Washington, DC, USA.
James TonsgardDepartment of Pediatrics, University of Chicago, Chicago, IL, USA.
Nicole J UllrichDepartment of Neurology, Boston Children's Hospital, Boston, MA, USA.
Bruce R KorfDepartment of Genetics, University of Alabama, Birmingham, AL, USA.
Michael J FisherDivision of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Scott R PlotkinCancer Center and Department of Neurology, Massachusetts General Hospital, Boston, MA, USA. splotkin@mgh.harvard.edu.
Neurofibromatosis Clinical Trials Consortium

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748U.S. Department of Defense W81XWH-12-1-0155
6 · The paper itself

Abstract

purposeBevacizumab treatment is associated with imaging and hearing responses in progressive vestibular schwannoma (VS) caused by NF2-related schwannomatosis (NF2-SWN). However, its effect on co-existing intracranial non-vestibular schwannomas (NVS) and meningiomas is unclear.

methodsWe retrospectively analyzed tumor volumes of non-target intracranial NVS and meningiomas in patients with NF2-SWN and progressive VS who were prospectively treated with bevacizumab for two years on the Neurofibromatosis Clinical Trials Consortium (NFCTC) trial NF104 (NCT01767792). Radiographic response (RR) or progression (PD) were defined as ≥ 20% decrease or ≥ 20% increase in tumor volume compared to baseline, respectively. All other responses were defined as stable disease.

resultsA total of 40 meningiomas in eight patients and 12 NVS in six patients were evaluated across 22 enrolled trial participants. On best response analysis, RR occurred in 13% (5/40) of meningiomas and in 42% (5/12) of NVS. On a per-patient basis, RR for meningioma occurred in 38% (3/8) of patients and for NVS in 67% (4/6) of patients. RR in two NVS were durable throughout the study period. During two years of treatment, PD occurred in 55% (22/40) of meningiomas and in 8% (1/12) of NVS. Median time to tumor progression was 15 months for meningiomas and was not reached for NVS.

conclusionsWe observed greater activity of bevacizumab against intracranial NVS compared to meningioma, evidenced by more favorable RR rates, durability of response, and rates of PD. Potential biological differences between meningiomas and schwannomas that underlie this differential response to bevacizumab warrant further investigation.

Indexed as

Angiogenesis InhibitorsAntineoplastic Agents, ImmunologicalBevacizumabMeningeal NeoplasmsMeningiomaNeurilemmomaNeurofibromatosesNeurofibromatosis 2Skin NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedAngiogenesis InhibitorsAntineoplastic Agents, ImmunologicalBevacizumabNeurofibromin 2BevacizumabMeningiomaNF2Non-vestibular schwannomaSchwannomatosis

Identifiers

PMID40434540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.